Ospelt, E, Hardison, H, Rioles, N, Noor, N, Weinstock, R, Cossen, K, Mathias, P, Smego, A, Mathioudakis, N, Ebekozien, O

Screening for autoantibodies associated with type 1 diabetes can identify people most at risk for progressing to clinical type 1 diabetes and provide an opportunity for early intervention. Drawbacks and barriers to screening exist, and concerns arise, as methods for disease prevention are limited and no cure exists today. The availability of novel treatment options such as teplizumab to delay progression to clinical type 1 diabetes in high-risk individuals has led to the reassessment of screening programs. This study explored awareness, readiness, and attitudes of endocrinology providers toward type 1 diabetes autoantibody screening.

Click here to view the article!

If you are a member of the T1DX-QI, you can view the full pdf in the portal.